Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$22.69
-5.5%
$20.77
$10.14
$28.42
$284.69M0.8679,315 shs186,714 shs
Cellectis S.A. stock logo
CLLS
Cellectis
$1.41
-3.4%
$1.42
$1.10
$2.81
$78.37M3.11142,297 shs39,491 shs
Cryoport, Inc. stock logo
CYRX
Cryoport
$5.90
-2.2%
$5.94
$4.58
$11.64
$295.81M1.92541,932 shs193,079 shs
SNDL Inc. stock logo
SNDL
SNDL
$1.30
+0.8%
$1.38
$1.24
$2.40
$341.61M3.682.02 million shs662,089 shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-1.15%-10.78%+11.42%+8.45%+99.67%
Cellectis S.A. stock logo
CLLS
Cellectis
-0.68%-5.19%-4.58%+4.29%-48.23%
Cryoport, Inc. stock logo
CYRX
Cryoport
-0.17%-10.53%+4.69%+1.34%-45.38%
SNDL Inc. stock logo
SNDL
SNDL
0.00%-3.01%-13.42%-20.86%-41.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
4.4233 of 5 stars
4.64.00.04.62.20.80.0
Cellectis S.A. stock logo
CLLS
Cellectis
3.0687 of 5 stars
3.55.00.00.01.82.50.6
Cryoport, Inc. stock logo
CYRX
Cryoport
3.3988 of 5 stars
4.41.00.00.03.73.30.6
SNDL Inc. stock logo
SNDL
SNDL
3.1166 of 5 stars
3.53.00.00.03.10.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.22
Buy$41.8684.47% Upside
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$6.67372.81% Upside
Cryoport, Inc. stock logo
CYRX
Cryoport
2.71
Moderate Buy$11.0086.44% Upside
SNDL Inc. stock logo
SNDL
SNDL
3.00
Buy$3.63178.85% Upside

Current Analyst Ratings Breakdown

Latest CLLS, SNDL, CDTX, and CYRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$47.00
5/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$31.00 ➝ $35.00
5/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
5/16/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$35.00 ➝ $50.00
5/13/2025
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$33.00 ➝ $35.00
5/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$46.00 ➝ $47.00
5/8/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/29/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$46.00 ➝ $46.00
4/16/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$302K942.69N/AN/A($1.82) per share-12.47
Cellectis S.A. stock logo
CLLS
Cellectis
$47.63M1.65N/AN/A$1.52 per share0.93
Cryoport, Inc. stock logo
CYRX
Cryoport
$232.13M1.27$0.35 per share16.95$9.45 per share0.62
SNDL Inc. stock logo
SNDL
SNDL
$927.61M0.37N/AN/A$3.47 per share0.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$22.93M-$29.47N/AN/AN/A-289.05%-69.64%-33.73%8/11/2025 (Estimated)
Cellectis S.A. stock logo
CLLS
Cellectis
-$101.06M-$0.86N/AN/AN/A-234.39%-74.55%-22.65%8/5/2025 (Estimated)
Cryoport, Inc. stock logo
CYRX
Cryoport
-$99.59M-$2.34N/AN/AN/A-70.08%-13.35%-6.43%8/5/2025 (Estimated)
SNDL Inc. stock logo
SNDL
SNDL
-$127.91M-$0.29N/AN/AN/A-12.11%-8.27%-6.96%8/7/2025 (Estimated)

Latest CLLS, SNDL, CDTX, and CYRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million
5/8/2025Q1 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.45-$1.66+$3.79-$1.66N/AN/A
5/7/2025Q1 2025
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
5/1/2025Q1 2025
SNDL Inc. stock logo
SNDL
SNDL
-$0.06-$0.04+$0.02-$0.04$214.60 million$142.38 million
3/18/2025Q4 2024
SNDL Inc. stock logo
SNDL
SNDL
-$0.01-$0.19-$0.18-$0.19$248.10 million$179.06 million
3/13/2025Q4 2024
Cellectis S.A. stock logo
CLLS
Cellectis
$0.06-$0.16-$0.22-$0.15$5.90 million$33.22 million
3/6/2025Q4 2024
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.28-$5.38-$0.10-$5.37N/AN/A
3/4/2025Q4 2024
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.33-$0.42-$0.09-$0.42$58.71 million$59.53 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
N/AN/AN/AN/AN/A
SNDL Inc. stock logo
SNDL
SNDL
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
3.54
3.54
Cellectis S.A. stock logo
CLLS
Cellectis
0.48
1.78
1.78
Cryoport, Inc. stock logo
CYRX
Cryoport
0.48
5.70
5.32
SNDL Inc. stock logo
SNDL
SNDL
0.10
5.61
4.16

Institutional Ownership

CompanyInstitutional Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Cryoport, Inc. stock logo
CYRX
Cryoport
92.90%
SNDL Inc. stock logo
SNDL
SNDL
N/A

Insider Ownership

CompanyInsider Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
7.64%
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Cryoport, Inc. stock logo
CYRX
Cryoport
10.10%
SNDL Inc. stock logo
SNDL
SNDL
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9012.55 million6.51 millionNo Data
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
Cryoport, Inc. stock logo
CYRX
Cryoport
1,02050.14 million44.44 millionOptionable
SNDL Inc. stock logo
SNDL
SNDL
580262.78 millionN/AOptionable

Recent News About These Companies

3 Marijuana Stocks For The Long Term Investing
These Cannabis Companies Are Repurchasing Shares
SNDL 1Q Loss Widens
SNDL Launches Rise Rewards Loyalty Program

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$22.69 -1.31 (-5.46%)
Closing price 04:00 PM Eastern
Extended Trading
$21.96 -0.73 (-3.22%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.41 -0.05 (-3.42%)
Closing price 04:00 PM Eastern
Extended Trading
$1.44 +0.03 (+1.77%)
As of 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cryoport stock logo

Cryoport NASDAQ:CYRX

$5.90 -0.13 (-2.16%)
Closing price 04:00 PM Eastern
Extended Trading
$5.90 +0.00 (+0.08%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

SNDL stock logo

SNDL NASDAQ:SNDL

$1.30 +0.01 (+0.78%)
Closing price 04:00 PM Eastern
Extended Trading
$1.29 -0.01 (-0.77%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.